Forma Therapeutics Holdings (FMTX) Announces FT-4202 Receives Orphan Drug Designation in Europe for Treatment of Sickle Cell Disease

Go back to Forma Therapeutics Holdings (FMTX) Announces FT-4202 Receives Orphan Drug Designation in Europe for Treatment of Sickle Cell Disease
(NASDAQ: FMTX) Delayed: 24.13 -0.13 (0.54%)
Previous Close $24.26    52 Week High
Open $24.66    52 Week Low
Day High $25.04    P/E N/A 
Day Low $23.63    EPS
Volume 354,815